Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

‘Tis the Season to Be Sniffly - Seasonal Influenza Boosts Vaccines Market

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
Acute viral respiratory infection influenza, or flu, strikes every winter, and several nations are preparing to tackle this illness through dedicated healthcare schemes, states a new report by healthcare experts GBI Research.

The new report* states that patients normally recover within a week or two from the associated fevers, sore throats, coughs, headaches and fatigue, but vulnerable individuals can develop the more severe disease pneumonia which can cause severe illness and even death. Both cases prove a serious public health problem that creates a huge social and economic burden for national healthcare systems, and affects the wider economy as a result of time taken off work.

However, safe and effective vaccines have been available for decades, and the 2009 H1N1 influenza pandemic increased public awareness of the disease, increasing demand for vaccines throughout the US, the UK, France, Italy, Spain, Germany and Japan. These developed countries offer a high awareness of public health and hygiene, wide vaccination coverage, and rising government support for immunization, presenting an attractive market for vaccine manufacturers. Their growing elderly populations also offer large numbers of high risk individuals, prompting wide scale immunization. GBI Research predicts that the influenza vaccine market will grow in these top seven countries at a Compound Annual Growth Rate (CAGR) of 3.9% during the 2011–2018 period, from $2.9 billion to $3.8 billion.

Governments in these nations have responded positively to the threat posed by pandemic and seasonal influenza outbreaks, often adopting national immunization programs to deal with the challenge of large-scale immunization in a short space of time. Through these programs, governments provide reimbursement of the provision of free treatment, immunizing those at risk of infection, while raising awareness of influenza among the general public. Every year during the influenza season in the UK, France, Italy, Spain and Germany, free doses of seasonal influenza vaccines are supplied to elderly people, pregnant women, chronically ill individuals and other high risk groups, based on the recommendations of the World Health Organization (WHO). In the US, influenza costs are completely reimbursed by Medicaid for the insured population.

The vaccinated population in the top seven countries accounted for 28.9% of the overall population in 2011, with the highest overall vaccination coverage rate (40.9%) seen in the US and the lowest (18.1%) in Italy. The vaccinated population in the top seven countries is forecast to increase to 32.9% in 2018.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Global Biosimilars Market Value Could Hit $55 Billion by 2020, says GBI Research
Promising pipeline in active development and government efforts to reduce healthcare spending.
Thursday, July 02, 2015
Big Pharma Embraces Biologics
Increased uptake of biologics boosts API revenues and promote growth in the biopharmaceutical market.
Friday, November 30, 2012
Biologics and Stem Cell Research Boost the Cell Culture Market
Cell culture market expected to grow at a CAGR of 9.3% between 2011 and 2018.
Thursday, November 15, 2012
Outsourcing in Asia to Shrink Japan’s Revenue Share
Pharma’s interest in outsourcing, combined with rising industrialization in India and China, will mark a drop in Japan’s share of the continent’s revenue.
Tuesday, November 06, 2012
World Awaits Biosimilars Boom
Biosimilars set to take a sizable chunk of the global biopharmaceuticals market by 2020, new report predicts.
Thursday, October 04, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!